Overactive Bladder With Urge Urinary Incontinence Clinical Trial
Official title:
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence
| Verified date | March 2023 |
| Source | Urovant Sciences GmbH |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder (OAB) and urge urinary incontinence (UUI) up to 48 weeks post-dose.
| Status | Completed |
| Enrollment | 80 |
| Est. completion date | July 20, 2022 |
| Est. primary completion date | November 18, 2021 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 40 Years to 79 Years |
| Eligibility | Inclusion Criteria: - Participant has symptoms of Overactive Bladder (OAB) (frequency and urgency) with Urge Urinary Incontinence (UUI) for a period of at least 6 months prior to screening. - Participant experiences = 1 episode of UUI per day. - Participant has not been adequately managed with = 1 oral or transdermal pharmacologic therapies for the treatment of their OAB symptoms. Exclusion Criteria: - Participant has symptoms of OAB due to any known neurological reason (e.g., spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc). - Participant has a predominance of stress incontinence in the opinion of the investigator, determined by participant history. - Participant currently uses or plans to use medications or therapies to treat symptoms of OAB, including nocturia. - Participants who have previously been treated with onabotulinumtoxinA for urological indications within 12 months of starting the Screening Bladder Diary, or any other toxin for urological indications, regardless of when treated (participants treated with onabotulinumtoxinA or other toxins for non-urological indications are eligible, regardless of when treated) |
| Country | Name | City | State |
|---|---|---|---|
| United States | Institute For Female Pelvic Medicine | Allentown | Pennsylvania |
| United States | Atrium Healthcare | Charlotte | North Carolina |
| United States | Great Lakes Physician PC / Western New York Urology Associates | Cheektowaga | New York |
| United States | Premier Urology Group, LLC | Edison | New Jersey |
| United States | Urology Center of Englewood | Englewood | New Jersey |
| United States | Accumed Research Associates - ClinEdge - PPDS | Garden City | New York |
| United States | Chesapeake Urology Associates | Hanover | Maryland |
| United States | Urology Specialists of The Carolinas | Huntersville | North Carolina |
| United States | Washington Urology & Urogynecology Associates | Kirkland | Washington |
| United States | Orange County Urology Associates | Laguna Hills | California |
| United States | University of Southern California - Norris Hospital | Los Angeles | California |
| United States | Coastal Clinical Research Inc | Mobile | Alabama |
| United States | Tri Valley Urology Medical Group | Murrieta | California |
| United States | Stanford University School of Medicine | Palo Alto | California |
| United States | Beaumont Hospital | Royal Oak | Michigan |
| United States | Precision Clinical Research LLC | Sunrise | Florida |
| United States | Urological Associates of Southern Arizona | Tucson | Arizona |
| United States | Urology of Virginia | Virginia Beach | Virginia |
| United States | Bay State Clinical Trials | Watertown | Massachusetts |
| United States | Iowa Clinic | West Des Moines | Iowa |
| Lead Sponsor | Collaborator |
|---|---|
| Urovant Sciences GmbH |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change From Baseline at Week 12 in Average Daily Number of Urgency Episodes | Average daily number of urgency episodes was calculated as the total number of urgency episodes recorded on a completed diary day within the visit window divided by the number of days the Bladder Diary was filled out. An urgency episode was defined as when a participant answered "Yes" to the question "Need to urinate immediately" on the bladder diary electronic case report form (eCRF). If a participant had more than 1 bladder diary filled out on the same day, then all the urgency episodes were summed together. The denominator used for calculating the average number only counted the days in which there was at least 1 completed bladder diary day within the visit window. Baseline was defined as the last non-missing measurement prior to the study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. | Baseline (Day 1) and at Week 12 | |
| Secondary | Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) | An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant, administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize participant and may require medical or surgical intervention to prevent any of outcomes listed above. TEAEs/TESAEs are defined as any event that began or worsened in severity after initial exposure of study treatment through 48 weeks after treatment administration or the date of the initiation of another overactive bladder medication, investigational agent, or surgical intervention, whichever occurred first. | Up to Week 48 |